Prostate Cancer

Treatment can safely be delayed in patients with low-grade prostate cancer who are carefully selected but then demonstrate disease progression after a period of active surveillance.

Nicholas J. Vogelzang, MD, from Comprehensive Cancer Centers of Nevada, discusses sequencing abiraterone acetate and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer.

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses findings from the READY trial that added dasatinib to docetaxel as a treatment for men with metastatic castration-resistant prostate cancer.

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.

Administration of docetaxel every 2 weeks in patients with CRPC was associated with significantly longer time to treatment failure, improved OS, and produced fewer adverse events.

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

Shortening the course of androgen blockade therapy from 36 months to 18 months when combined with radiation therapy does not appear to compromise outcomes in patients with high-risk prostate cancer

A large, retrospective study has found that high-risk prostate cancer that can only be detected through PSA testing is more likely to occur among men over the age of 75 and in African Americans.

Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA's priority review program.

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.

James Mohler, MD, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors.

Researchers have discovered that the oncogenic function of a particular protein in CRPC can cause the cancer to spread without stimulation by male hormones.

Men with prostate cancer who had a high baseline risk of skeletal complications developed more fractures and had a higher mortality risk after long-term ADT when compared to men with lower baseline risk factors.

The treatment of late-stage prostate cancer is shifting; with the approval of two new oral agents there are now more options for men with metastatic prostate cancer then just two years ago.

Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.